Signals, Powered By EquityPandit
Roche Holding AG and Cipla Ltd have begun selling a covid-19 antibody-drug cocktail to treat non-hospitalized patients who face high risks of their infections turning severe. The drug which has been developed by New York-based Regeneron Pharmaceuticals Inc. comprises two antibodies casirivimab and imdevimab. An antibody cocktail is a mix of two or more unique biological drugs that act like human antibodies to help fight off infection.
“We are optimistic that the availability of antibody cocktail in India can help in minimizing hospitalization, ease the burden on healthcare systems and play a key role in the treatment of high-risk patients before their condition worsens,” V. Simpson Emmanuel, managing director, and chief executive officer of Roche Pharma India, said in the statement. In total, the antibody-drug cocktail can potentially benefit 200,000 patients as each of the 100,000 packs that will be available in India can treat two patients, Roche and Cipla said.
The launch of the cocktail follows an emergency authorization from the Drugs Controller General of India earlier this month.
Stock Covered in the news
